Skip to main content
Home
Latest news
Browse topics
Lupus Rheumatoid arthritis Spondyloarthropathies COVID-19 Browse all topics
In focus
Bimekizumab: Dual IL-17A/IL-17F inhibition in SpA Anifrolumab for the treatment of SLE JAK inhibitor safety: Weighing up the data and understanding the risks Rituximab and rheumatology practice in the COVID-19 era Safety snapshot: Upadacitinib in patients with PsA Repurposing rheumatology drugs for COVID-19 Telemedicine in rheumatology: COVID-19 and beyond Managing PsA in resource-limited settings
Conferences
ACR Convergence 2022 EULAR 2022 Congress
About us
Medicine Matters Rheumatology
EXTENDED SEARCH

COVID-19


Browse news, expert commentary, and educational content on COVID-19.


Highlights

24-10-2022 | COVID-19 | News

Prophylactic antivirals may help prevent symptomatic COVID-19 in rituximab-treated patients

Pre-exposure prophylaxis with tixagevimab and cilgavimab may be an effective strategy to prevent symptomatic SARS-CoV-2 infection among people with rheumatic diseases treated with rituximab, suggest findings from a real-world study.

30-08-2022 | COVID-19 | News

Studies bolster evidence for COVID-19 vaccination in young people with RMDs

Findings from three studies provide further support for the effectiveness and safety of COVID-19 vaccines in young people with rheumatic and musculoskeletal diseases.

25-08-2022 | COVID-19 | News

‘Substantial improvement’ in COVID-19 outcomes over time for RMD patients

The proportion of people with rheumatic and musculoskeletal diseases experiencing severe COVID-19 has declined since the beginning of the pandemic, particularly during the recent Omicron wave, US researchers report.

Rituximab and rheumatology practice in the COVID-19 era

How can rheumatologists respond to the challenges associated with rituximab use during the pandemic?

Repurposing rheumatology drugs for COVID-19

11-11-2022 | COVID-19 | News

FDA authorizes anakinra for severe COVID-19

04-01-2022 | COVID-19 | News

Anakinra authorized for COVID-19 pneumonia in Europe

02-11-2021 | COVID-19 | News

RECOVERY: No evidence for colchicine benefit in COVID-19

12-10-2021 | COVID-19 | News

EULAR updates guidance on immunomodulatory treatment for COVID-19

COVID-19 vaccination in patients with rheumatic diseases

Get answers to key questions with recommendations from professional organizations

COVID-19 guidance for rheumatologists

04-06-2022 | EULAR 2022 | Conference coverage | News

Support for pausing methotrexate only after second COVID-19 vaccine dose

20-05-2022 | Telehealth | News

EULAR issues guidance on telemedicine in rheumatology

Repurposing rheumatology drugs for COVID-19

Experts discuss the rationale, data on different agents, and the potential impact on rheumatology practice.

Keep up with podcasts on this topic, available on

Telemedicine in rheumatology

Experts discuss the increasing use of telemedicine in rheumatology during the COVID-19 pandemic.
Image Credits